250 related articles for article (PubMed ID: 32061484)
1. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
[TBL] [Abstract][Full Text] [Related]
2. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel STAT3 DNA binding domain inhibitors.
Wu B; Payero B; Taylor S; Oyelere AK
Future Med Chem; 2021 Aug; 13(15):1253-1269. PubMed ID: 34180263
[No Abstract] [Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Wei M; Xie M; Zhang Z; Wei Y; Zhang J; Pan H; Li B; Wang J; Song Y; Chong C; Zhao R; Wang J; Yu L; Yang G; Yang C
Eur J Med Chem; 2020 Nov; 206():112677. PubMed ID: 32823005
[TBL] [Abstract][Full Text] [Related]
6. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
7. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
[TBL] [Abstract][Full Text] [Related]
8. Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
Sodji QH; Kornacki JR; McDonald JF; Mrksich M; Oyelere AK
Eur J Med Chem; 2015; 96():340-59. PubMed ID: 25899338
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
10. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
11. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
12. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK
J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
19. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
